Literature DB >> 7815362

Is the "atypical" beta-receptor in the rat stomach fundus the rat beta 3 receptor?

M L Cohen1, J G Granneman, A Chaudhry, K W Schenck, D J Cushing, A D Palkowitz.   

Abstract

The rat gastric fundus is known to possess an "atypical" beta-adrenergic receptor that mediates relaxation to isoproterenol. The purpose of this study was to characterize the relationship between this "atypical" beta receptor in the rat stomach and the cloned rat beta 3 receptor by taking advantage of highly selective pharmacological and molecular biological probes of the beta 3 receptor. Nuclease protection analysis of RNA from the rat gastric fundus identified beta 3 receptor mRNA whose levels in the stomach were exceeded only by those in adipose tissue. Pharmacological analysis of the recombinant rat beta 3 receptor expressed in Chinese hamster ovary cells indicated low affinity of propranolol with a Ki value of 2.3 microM. Therefore, 0.3 microM propranolol was chosen as a concentration that would completely block beta 1 and beta 2 receptors (Ki = 1-5 nM) but would leave beta 3 receptors largely intact in the rat stomach fundus. In the presence of propranolol, several beta-adrenergic receptor agonists relaxed the rat stomach fundus with a rank potency order of (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino]-propyl]1,3- benzodioxole-2,2-dicarboxylate (CL316,243) > isoproterenol > norepinephrine = epinephrine = dl-4-3[(1,1-dimethylethyl)amino]-2- hydroxylproproy]1,3 dihydro-2H-benzimidazol-2-one hydrochloride (CGP12177) > clenbuterol > terbutaline > pindolol. Isoproterenol, norepinephrine and epinephrine were full agonists, whereas (R,R)-5-[2-[[2-(3-chlorophenyl)-2- hydroxyethyl]-amino]-propyl]1,3-benzodioxole-2,2-dicarboxylate was only a partial agonist with 66% intrinsic activity relative to isoproterenol.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7815362

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Targeted gene disruption reveals a leptin-independent role for the mouse beta3-adrenoceptor in the regulation of body composition.

Authors:  J P Revelli; F Preitner; S Samec; P Muniesa; F Kuehne; O Boss; J D Vassalli; A Dulloo; J Seydoux; J P Giacobino; J Huarte; C Ody
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Alternative splicing generates two isoforms of the beta3-adrenoceptor which are differentially expressed in mouse tissues.

Authors:  B A Evans; M Papaioannou; S Hamilton; R J Summers
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

3.  Aryl propanolamines: comparison of activity at human beta3 receptors, rat beta3 receptors and rat atrial receptors mediating tachycardia.

Authors:  M L Cohen; W Bloomquist; A Kriauciunas; A Shuker; D Calligaro
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

4.  Atypical responses of rat ileum to pindolol, cyanopindolol and iodocyanopindolol.

Authors:  A Hoey; C Jackson; G Pegg; M Sillence
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

5.  Tissue functions mediated by beta(3)-adrenoceptors-findings and challenges.

Authors:  Martin C Michel; Peter Ochodnicky; Roger J Summers
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-06-03       Impact factor: 3.000

6.  Expression of beta 3-adrenoceptor mRNA in rat tissues.

Authors:  B A Evans; M Papaioannou; V R Bonazzi; R J Summers
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

7.  Rat β₃-adrenoceptor protein expression: antibody validation and distribution in rat gastrointestinal and urogenital tissues.

Authors:  Hana Cernecka; Wisuit Pradidarcheep; Wouter H Lamers; Martina Schmidt; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-08-30       Impact factor: 3.000

8.  Downregulation of propranolol-sensitive beta-adrenoceptor signaling after inhibition of nitric oxide synthesis.

Authors:  Erin J Whalen; James N Bates; Alan Kim Johnson; Stephen J Lewis
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.